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Abstract 
Tumor cells in regional lymph nodes are a key prognostic marker of survival and 
predictive marker of response to adjuvant chemotherapy in colorectal cancer.  
However, clinicopathologic techniques to detect lymph node metastases 
remain imperfect, and ~30% of patients with lymph nodes negative by histology 
(pN0) develop recurrent disease, reflecting occult metastases that escape 
detection.  These observations underscore an unmet clinical need for accurate 
approaches to identify occult nodal metastases in colorectal cancer patients.  
GUCY2C is a receptor whose expression normally is restricted to intestinal 
epithelial cells, but is universally over-expressed by colorectal cancer cells.  A 
prospective, multicenter, blinded clinical trial established the prognostic utility of 
GUCY2C qRT-PCR to detect occult nodal metastases in pN0 colorectal cancer 
patients.  Molecular staging revealed that ~13% of pN0 patients were free of 
cancer cells, while ~87% had GUCY2C results that suggested occult metastases.  
The presence of occult nodal metastases was the most powerful independent 
predictor of time to recurrence and disease-free survival.  These observations 
establish the utility of molecular detection of occult nodal metastases for 
assessing prognostic risk in pN0 colorectal cancer patients.  Advancing GUCY2C 
into staging paradigms in clinical laboratories will require validation in 
independent patient populations, definition of the relationship between the 
quantity of occult tumor metastases and risk, and determination of the utility of 
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Colorectal cancer continues to be the 4th most frequent tumor, with ~140,000 
new cases annually in the U.S., and the 2nd leading cause of cancer-related 
mortality [1].  Colorectal cancer causes ~10% of cancer-related deaths in the 
U.S., with a mortality rate approaching ~50% [1-3].  Mortality reflects metastases: 
~20% of colorectal cancer patients have unresectable disease at presentation 
(stage IV) and >30% will develop metastases during the course of their disease 
[2-5].  Surgery continues to have the greatest impact on survival.  However, 
while “curative” surgery removes all detectable tumor and is most successful in 
early-stage disease, occult metastases result in relapse [1-3, 6-9].  Recurrence 
rates range from ~10% for disease limited to mucosa (stage I) to >60% for tumors 
metastatic to lymph nodes (stage III) [1-3, 6-19]. 
2.  Staging colorectal cancer 
Historically, the single most important prognostic determinant of clinical 
outcomes in colorectal cancer is tumor cells in regional lymph nodes [1-6, 9, 20-
24].  The importance of cancer cells in lymph nodes is underscored by the 
discovery that the biology of nodal and hematogenous metastases are 
identical [25], and tumor cells in lymph nodes offer a unique diagnostic window 
for prognostic and predictive risk stratification with respect to distant metastases 
that define outcomes.  Although histopathology remains the standard 
paradigm, staging imprecision by conventional microscopy reflects 
methodological limitations [2, 5, 24].  Microscopic visualization is insensitive, with 
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a lower limit for detection of ~1 cancer cell in 200 normal cells [26].  Also, there is 
an inherent sampling error and typically less than 0.1% of available lymph node 
tissue is examined by microscopy [4, 5, 26].  These limitations are highlighted by 
the frequency of post-surgical disease recurrence.  In stage I and II (pN0) 
patients, who represent nearly 50% of all colorectal cancer patients, tumors are 
limited to the bowel wall without histological evidence of lymph node 
metastases or dissemination beyond intestine and should be cured by surgery.  
However, recurrence rates as high as 30% in stage I and 50% in stage II have 
been observed [2, 3, 5, 24].  In stage III, where all obvious tumor, including lymph 
nodes harboring metastases, is removed, recurrence rates >70% have been 
described [2, 10, 12-15, 17-19, 27, 28].  In pN0 patients, recurrences reflect a 
mixture of true pN0 lesions and occult stage III or IV lesions undetected by 
histopathology [2, 4, 5, 12, 21, 29, 30]. 
3.  Adjuvant therapy in colon cancer 
Beyond prognosis, stage identifies patients that receive adjuvant therapy.  
Chemotherapy administered after surgery to patients with stage III colon cancer 
enhances survival, increasing time-to-recurrence by 40% and overall survival by 
30% [6, 20, 31-37].  Also, introduction of molecularly targeted therapeutics 
increases 5 year median and overall survival in stage IV patients, from ~7% to 
>30% [38].  In contrast, the benefit of adjuvant chemotherapy in pN0 colon 
cancer patients is unclear, with only small benefits in stage II patients in some, 
but not all, studies [2, 3, 6, 7, 20, 22, 23, 39].  This uncertainty of therapeutic 
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benefit is reflected in the evolution of treatment guidelines, in which adjuvant 
therapy is optional in pN0 patients with clinicopathologic characteristics 
suggesting poor prognostic risk [9, 40-42].  Heterogeneous responses to therapy 
in pN0 patients reflect, in part, the variability of occult lymph node metastases 
[4, 5, 21, 24, 43-45].  Consequently, there is an unmet clinical need for better 
methods that detect prognostic occult nodal metastases, to identify pN0 
patients who could benefit from adjuvant therapy [6, 38] and who are 
candidates for pharmacogenomic testing to identify critical mutations defining 
responses to molecular targeted agents [46]. 
4.  Staging and molecular diagnostics 
Histology remains the clinical standard for staging, reflecting the prognostic and 
predictive relationship between tumor cells in lymph nodes and outcomes [1-6, 
9, 20-23].  However, this approach underestimates metastases.  In lymph nodes 
burdened with metastases, ~70% contain metastases that are <0.5 cm which 
often escape detection by standard clinicopathology approaches reflecting 
their size [2, 3, 5, 24].  In contrast, evolving technologies including qRT-PCR, may 
offer the most sensitive and specific evaluation of nodal metastases [5, 24].  
Advantages of molecular staging include the ability to sample the entire 
specimen and to detect one tumor cell in ~107 normal cells [5, 24].  While 
staging by RT-PCR has yielded inconsistent results, reflecting inadequate 
population size without appropriate clinical follow-up and variable analytic 
techniques, meta-analyses suggest the prognostic value of occult nodal 
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metastases detected by RT-PCR in pN0 colorectal cancer patients [4, 5, 21, 30, 
45, 47]. 
5.  Guanylyl cyclase C (GUCY2C), a biomarker for colorectal cancer 
GUCY2C, one member of a family of receptor-enzyme proteins synthesizing 
guanosine 3’ 5’ cyclic monophosphate (cyclic GMP; cGMP), is specifically 
expressed by intestinal epithelial cells [48-57].  GUCY2C is the cognate receptor 
for the paracrine hormones guanylin and uroguanylin, which interact with the 
extracellular domain, activating the cytoplasmic catalytic domain, inducing 
cGMP accumulation [53, 56, 58-64].  GUCY2C regulates the dynamic 
progression of cells along the crypt-villus and crypt-surface axis, coordinating 
homeostatic processes including proliferation, DNA repair, metabolic 
programming, lineage-specific cell fate, and epithelial-mesenchymal 
interactions organizing that axis [65-77].  Further, guanylin and uroguanylin are 
gene products universally lost early in colorectal neoplasia [78-82].  Moreover, 
eliminating GUCY2C expression increases the burden of tumors in mouse models 
of intestinal cancer induced by inherited germline mutations or chemical 
carcinogenesis, reflecting dysregulation of the cell cycle and DNA repair [68].  
These observations suggest that GUCY2C is a tumor suppressor regulating 
homeostasis whose silencing reflecting the loss of paracrine hormones 
contributes to neoplasia [66-68, 73, 83].  Of significance, GUCY2C was detected 
in all samples of normal intestine, but not in any extra-gastrointestinal specimens 
[43, 47, 49, 50, 58].  Also, GUCY2C protein or mRNA was detected near-
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universally (>95%) in all primary and metastatic human colorectal tumors 
regardless of anatomical location or grade, but not in tumors arising outside the 
GI tract [43, 47, 49, 50, 58, 81, 84-87].  Further, GUCY2C mRNA and protein are 
over-expressed by >80% of colorectal cancers [84, 88, 89].  Restriction of 
expression normally to intestinal epithelial cells, but universal over-expression by 
colorectal cancer cells highlights the use of GUCY2C as a biomarker for 
metastatic colorectal cancer [45]. 
6.  GUCY2C as a biomarker for occult colorectal metastases 
Early retrospective studies suggested that in colorectal cancer patients GUCY2C 
mRNA detected by RT-PCR predicted risk of disease recurrence [47].  These 
initial observations supported an adequately powered, prospective, blinded 
clinical trial of the use of GUCY2C qRT-PCR to identify prognostically important 
occult nodal metastases using an analytically validated assay.  This trial 
provided level 1 evidence [90] of the utility of RT-PCR for identifying prognostic 
lymph node metastases in colorectal cancer patients.  This study (a) compared 
staging of colorectal cancer patients by GUCY2C RT-PCR with histopathology; 
(b) compared the predictive utility of staging by GUCY2C qRT-PCR or 
histopathology for recurrent colorectal cancer; and (3) developed a predictive 
model for disease recurrence employing GUCY2C qRT-PCR as an independent 
biomarker of risk. 
6.1.  Evolution of molecular diagnostics supporting prospective biomarker 
validation.  Validation of GUCY2C as a biomarker for staging colorectal cancer 
 11 
patients presented unexpected challenges reflecting the untested character of 
quantitative (q)RT-PCR to detect clinically significant biomarkers in clinical trials 
involving substantial numbers of patients.  These studies depended on an 
analytically validated assay platform to quantify GUCY2C mRNA reliably across 
>5,000 specimens.  Moreover, the validity of transcript quantification by qRT-PCR 
relies on the equivalence of reaction efficiencies in individual incubations, a 
characteristic that remarkably varies reflecting differences between patients, 
specimens, and reaction conditions.  To compare GUCY2C mRNA quantities in 
~20,000 qRT-PCR reactions, a platform was needed that incorporated 
adjustments to correct for variations in individual reaction efficiencies. 
• Validation of qRT-PCR assay for GUCY2C [88].  Analytic performance 
characteristics of the qRT-PCR assay for GUCY2C were defined employing 
GUCY2C complimentary (c)RNA standards.  Analysis using linear mixed 
models of the relationship between GUCY2C cRNA concentrations and 
threshold cycles produced in the PCR phase of the reaction yielded a mean 
intercept of 42.36 (95% CI: 41.94, 42.79), mean slope of -3.53 (95% CI: -3.62, -
3.44), and an average amplification slope efficiency of 92%.  This assay 
exhibited a broad dynamic range, with linearity from 2.5 x 101 to 2 x 106 
copies, and high sensitivity, with a limit of quantification of 25 copies.  The 
assay was robust, with plate-to-plate variability (CV) of 1% and within-plate 
variability of <5% across all cRNA concentrations.  These performance 
characteristics applied across various biological matrices, including human 
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lymph nodes.  Clinicopathologic characteristics were established using total 
RNA extracted from lymph nodes with metastases identified by histology (true 
positives, 15 nodes) and from patients without colon cancer (true negatives; 
164 nodes).  Negative nodes exhibited median GUCY2C copy numbers <50 
while positive nodes exhibited median copy numbers >1,000.  Evaluation of 
these performance characteristics using receiver-operator curve analysis 
revealed a sensitivity of 93% and specificity of 97%.  These robust 
performance characteristics suggest the suitability of GUCY2C qRT-PCR for 
examining the utility of that marker for staging colorectal cancer patients. 
• Relative qRT-PCR incorporating efficiency adjustments.  In PCR, DNA 
templates are enzymatically replicated at each cycle and copies created in 
each cycle emit a fluorescence signal proportional to the number of 
templates.  For each PCR reaction, the fluorescence signal is measured after 
each cycle.  With the cycle number, fluorescence measures constitute a 
kinetic PCR amplification history for each reaction.  Ideal reactions are 
described by an exponential (base 2) growth model.  In reality, not all 
templates are duplicated in a reaction cycle and the proportion of 
templates that are duplicated at each cycle is the amplification efficiency.  
This is a key issue in PCR quantification because many reactions do not have 
ideal or similar efficiencies, while comparisons of results between reactions 
presume equal efficiencies.  Thus, variations in estimating GUCY2C expression 
reflecting heterogeneity of efficiencies between reactions could hide true 
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differences reflecting the presence of metastatic tumor cells.  We developed 
a four-parameter logistic model which provides a method for efficiency-
adjusted relative RT-PCR quantification based on estimates from the 
parameterized logistic model fitted to the full kinetic data from each RT-PCR 
reaction [45, 91].  The efficiency-adjusted relative RT-PCR quantification using 
the parameterized logistic model fitted to the full kinetic data provides more 
accurate and precise estimates of individual PCR reaction efficiencies than 
traditional efficiency estimates based on exponential growth models [88].  
Thus, traditional exponential growth models were characterized by up to 5-
fold greater variability and 6-fold greater bias in normalized estimates of 
GUCY2C expression, compared to the parameterized logistic model.  Further, 
~80% of individual RT-PCR reactions for GUCY2C or the reference gene β-
actin provided insufficient exponential growth phase (<4 cycles) to apply 
traditional models for efficiency adjustments, suggesting that most reactions 
would be uninformative using traditional approaches.  This new method for 
efficiency-adjusted relative qRT-PCR based on logistic models minimizes bias 
and variability, maximizes precision and accuracy, and preserves the 
integrity of information available from all reactions [45, 91-93].  Of 
significance, this approach accommodates estimation of target analyte 
expression relative to reference genes using replicate reactions.  Given these 
advantages, this technique was applied to analyze GUCY2C expression to 
detect occult metastases in lymph nodes of colorectal cancer patients. 
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6.2.  GUCY2C qRT-PCR to stage colorectal cancer patients 
• Study design.  This was a prospective multicenter clinical trial in which 
investigators and clinical personnel were blinded to results of qRT-PCR 
analyses while laboratory personnel and analysts were blinded to 
clinicopathology information [45].  To have at least 80% power to detect a 
hazard ratio of 1.6 (P<0.05, 2-sided), an established threshold for stage-
specific risk stratification[94], 225 pN0 patients were required. 
• Study population.  Between March 2002 and June 2007, 273 stage 0-II pN0 
and 87 stage III pN1 colorectal cancer patients were enrolled at one of 9 
hospitals in the U.S. and Canada [45].  Patients were ineligible if they had a 
previous history of cancer, metachronous extra-intestinal cancer, or 
perioperative mortality associated with tumor resection. 
• Analytic approaches 
Pathology.  Lymph nodes, and tumor specimens when available (51%), were 
frozen at -80°C within one hour to minimize warm ischemia.  Half of each 
resected lymph node was fixed with formalin and embedded in paraffin for 
histological examination.  Specimens from pN0 patients were subjected to qRT-
PCR if (1) tumors, where available, expressed >30 copies GUCY2C mRNA, the 
baseline amount expressed in normal lymph nodes, and (2) at least one lymph 
node yielding RNA of sufficient integrity was available [88].  GUCY2C in tumors 
was lower than background in 14 patients who were excluded from analysis 
[88].  Analysis of the 2,656 lymph nodes available from the remaining 259 pN0 
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patients revealed 86 yielding RNA of insufficient integrity by β-actin qRT-PCR, 
excluding two additional patients [88].  Overall, the 257 pN0 patients who were 
eligible provided 6,699 lymph nodes (range 2-159, median 21 lymph 
nodes/patient) for histopathologic examination, of which 2,570 nodes (range 1-
33, median 8 lymph nodes/patient) were eligible for analysis by qRT-PCR.  
Greater numbers of lymph nodes available for histology compared to molecular 
analysis from pN0 patients includes those collected after formalin fixation or <5 
mm in diameter, below the limit for accurate bisection of fresh tissue. 
RT-PCR.  GUCY2C and β-actin mRNA was quantified using qRT-PCR by an 
analytically validated assay [88] employing logistic regression of amplification 
profiles from individual RT-PCR reactions, providing an efficiency-adjusted 
relative quantification [91]. 
Statistics.  In the absence of established methodologies to define optimal 
cutpoints for molecular markers from incomplete and variable collections of 
lymph nodes, it was established a priori that nodes in which relative GUCY2C 
mRNA was higher than or equal to the overall median would be considered 
pN0(mol+) while those lower than the median would be considered pN0(mol-) 
[45].  Patients were considered categorically pN0(mol+) if >1 lymph nodes were 
positive.  The primary clinical endpoint was time to recurrence, measured from 
date of surgery to time of last follow-up, recurrence event or death [95].  The 
secondary clinical outcome was disease-free survival, defined as time from 
surgery to any event regardless of cause [95].  Date of recurrence was 
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established by radiography, laboratory studies, physical exam, and/or histology.  
Simultaneous prognostic effects of parameters, including T stage, grade, tumor 
location, lymphovascular invasion, chemotherapy, total lymph nodes harvested, 
and pN0 molecular status [3], were estimated employing Cox regression 
analysis.  The multivariable model for each outcome included all prognostic 
measures, to establish the additional independent prognostic effect of 
molecular status. 
6.3.  Results from prospective clinical trial 
• Occult metastases and disease recurrence [45].  GUCY2C expression, 
reflecting occult metastases, was detected in at least one lymph node from 
225 (87.5%) patients with pN0 colorectal cancer [45].  These data suggest 
that, unexpectedly, most patients staged as node-negative by traditional 
histopathology harbor occult metastases.  The working hypothesis suggests 
that staging based on GUCY2C qRT-PCR should better predict colorectal 
cancer recurrence than histology.  Thus, patients who are pN0(mol+) by 
GUCY2C qRT-PCR are at greater risk for recurrent disease than patients who 
are pN0(mol-).  With a median follow-up of 24.0 months (range 1.8 to 62.7) for 
pN0(mol+) patients and 35.9 months (range, 2.5 to 62.1) for pN0(mol-) 
patients, 20.9% (CI, 15.8-26.8%) of patients with, but only 6.3% (CI, 0.8-20.8%) 
without, occult metastases developed recurrent disease (p=0.006) [45].  Both 
GUCY2C-negative patients who developed recurrent disease provided <2 
lymph nodes for analysis by qRT-PCR, perhaps reflecting the requirement, by 
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any staging technique, for adequate lymph node sampling [2, 3, 96-102].  
Further, GUCY2C mRNA conferred a worse prognosis among stage I and II 
patients and those with colon and rectal cancer.  Moreover, occult 
metastases were associated with reduced disease-free survival in patients 
with tumors of different stages and locations.  Time to recurrence and 
disease-free survival in pN0(mol+) patients were comparable to that of 
patients with stage III pN1 (stage IIIA + IIIB) disease, all of whom have 
histologically detectable nodal metastases [45]. 
• GUCY2C is an independent prognostic variable [45].  Occult lymph node 
metastases detected using GUCY2C qRT-PCR should enhance multivariable 
analyses incorporating known prognostic indicators to improve identification 
of patients with increased prognostic risk.  Cox proportional-hazards analyses 
revealed that the established clinicopathologic parameters, including T 
stage, grade, tumor location, lymphovascular invasion, therapy, and total 
lymph nodes harvested, did not contribute substantially to prognosis.  
However, GUCY2C qRT-PCR provided the most powerful independent 
prognostic information, and patients who were pN0(mol+) experienced 
earlier time to recurrence (absolute event rates: pN0(mol-) 6.3%, pN0(mol+) 
20.9%; hazard ratio 4.66 [1.11-19.57]; p=0.035) and reduced disease-free 
survival (absolute event rates: pN0(mol-) 12.5%, pN0(mol+) 26.2%; hazard ratio 
3.27 [1.15-9.29]; p=0.026) [45]. 
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Occult metastases detected by GUCY2C qRT-PCR for categorical risk 
stratification in pN0 colorectal cancer.  Prospective detection of occult 
metastases by GUCY2C qRT-PCR was an independent prognostic marker of risk 
in pN0 colorectal cancer patients.  Molecular staging revealed that ~13% of pN0 
patients were free of tumor cells, while ~87% harbored occult metastases by 
GUCY2C qRT-PCR.  Interestingly, while a high proportion of pN0 patients 
harbored occult metastases by GUCY2C, ~70% of pN0 patients will not recur [2, 
3].  Similarly, by comparison, only ~50% of stage III patients ultimately develop 
recurrent disease, although all have histology-detectable lymph node 
metastases [2, 3].  Reconciliation of this apparent inconsistency requires the 
realization that nodal metastases, regardless of methods used to detect them, 
do not assure recurrence but, rather, are a marker of risk.  Analyses using 
GUCY2C qRT-PCR suggests recurrence rates for pN0(mol+) patients with occult 
metastases that are nearly identical to those for stage III pN1 patients [2], the 
earliest stage in which all patients have microscopy-detectable metastases [1, 
2].  This analysis is the first to demonstrate the utility of molecular analysis to 
detect prognostic occult metastases in lymph nodes in an adequately 
powered, prospective trial with sufficient longitudinal follow-up employing 
analytically validated assays.  Indeed, the absence of this level of evidence has 
been one limitation to the translation of these paradigms to patient 
management [4, 5].  These considerations underscore the importance of future 
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validation with independent cohorts to confirm the prognostic utility of GUCY2C 
qRT-PCR in colorectal cancer. 
There is an established relationship between tumor burden, quantified as the 
number of lymph nodes harboring tumor cells by microscopy, and prognostic 
risk in colorectal cancer patients.  Assuming that adequate numbers of nodes 
are available for review [2, 3, 96-102], stage III patients with >4 lymph nodes 
harboring metastases exhibit a recurrence rate that is ~50-100% greater than 
those with <3 involved nodes [2, 3].  As in histology-based analyses, one 
limitation of our prospective trial was the variable number of lymph nodes 
available for qRT-PCR from individual patients.  Additionally, lymph nodes <5 mm 
were excluded, reflecting size limits for fresh tissue bisection, although they are a 
rich source of tumor metastases [103, 104].  These considerations suggest that 
the precision of staging by molecular analyses will benefit from optimum lymph 
node sampling to incorporate tumor burden into prognostic risk stratification. [4, 
5, 21].  Our working hypothesis suggested that there is an inverse relationship 
between the number of lymph nodes that contain occult metastases and risk.  
Specifically, it was hypothesized that patients with more lymph nodes containing 
occult metastases will have a greater prognostic risk compared to patients with 
fewer involved lymph nodes.  In an exploratory analysis, we examined the 
subset of pN0 patients who provided ≥12 lymph nodes for molecular analysis, 
then applied standard AJCC definitions for pN1 and pN2 [2, 3].  This analysis 
revealed that individuals with 0-3 involved nodes exhibited a prognostic risk 
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similar to pN0(mol-) patients (5.9% versus 8.3%) [45].  Conversely, those with >4 
involved nodes exhibited a risk (<3 versus >4, p=0.027) identical to patients with 
stage III pN1 disease [45].  Improved risk stratification by integrating occult 
metastases and estimates of tumor burden underscores the importance of 
adequate lymph node sampling for optimum molecular [4, 5, 21], as well as 
histological [2, 3, 99, 100], staging in colorectal cancer.  Moreover, the issue of 
adequacy of lymph node sampling in the context of the evolving prognostic 
and predictive significance of molecular staging is highlighted by the 
emergence of limited access surgical techniques for colon cancer like 
laparoscopic-assisted colectomy [105].  Indeed, the success of these novel 
surgical approaches, with their inherent restricted opportunities for diagnostic 
tissue collection [105], will be informed substantially by the co-evolution of 
molecular staging and the requirements for adequate lymph node collections 
to provide the richest source of prognostic and predictive information for 
patient management. 
Beyond the number of lymph nodes harboring metastases, there is an emerging 
relationship between the volume of cancer cells in individual nodes, tumor 
burden, and prognostic risk [2, 106].  Metastatic foci >0.2 mm are associated 
with increased disease recurrence [2].  However, the relationship between 
individual tumor cells or nests <0.2 mm and risk is unknown [2].  The emergence 
of qRT-PCR provides an unprecedented opportunity for quantification of 
metastatic burden in tissues.  The enhanced sensitivity of qRT-PCR [107], with 
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optimum sampling of tissue volumes and capability for single cell discrimination, 
may identify occult cancer cells in lymph nodes below the threshold of 
prognostic risk [2], limiting the specificity of molecular staging [45].  Our 
prospective study was not designed to identify a quantitative threshold defining 
risk.  Indeed, one limitation of that study was the requirement to define a priori 
the diagnostic threshold for GUCY2C.  In the future, it will be essential to define 
the quantitative relationship between marker expression and disease risk that 
incorporates estimates of tumor burden to optimize prognostic sensitivity and 
specificity [45].  Indeed, the potential for qRT-PCR to quantify occult metastases 
across all lymph nodes harvested, providing an integrated correlation of tumor 
burden and risk, further reinforces the central importance of empirically defining 
the number of lymph nodes required to provide optimum prognostic and 
predictive information to improve patient management. 
7.  Future Considerations 
The most significant prognostic marker of survival and predictive marker of 
response to adjuvant chemotherapy in colorectal cancer is the histologic 
detection of metastatic tumor cells in lymph nodes [1-6, 9, 20-23].  Despite its 
significance, approaches that evaluate lymph node metastases are 
inadequate and ~30% of pN0 patients develop disease recurrence, reflecting 
occult metastases that evade identification by established approaches [2-5, 21, 
24, 43, 44, 108].  These observations reinforce the clinical need for new 
approaches to more accurately evaluate occult nodal metastases in colorectal 
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cancer patients.  We have completed a prospective, multicenter, blinded 
clinical trial that for the first time demonstrated the utility of molecular staging by 
GUCY2C qRT-PCR lymph node assessment to predict prognostic risk [45].  Occult 
nodal metastases defined by GUCY2C qRT-PCR was the most powerful 
independent indicator of prognostic risk in pN0 patients, providing the first level 1 
evidence that supports the association of prognostic risk and occult nodal 
metastases [90].  These observations underscore the utility of molecular 
biomarker platforms generally, and GUCY2C qRT-PCR specifically, for staging 
patients with pN0 colorectal cancer.  Translation of these preliminary studies into 
clinically applicable staging algorithms will require several essential analyses 
over the next several years. 
• The prognostic utility of GUCY2C qRT-PCR for categorical identification 
(yes/no) of occult metastases as a marker of disease recurrence will require 
validation in an independent patient cohort.  This approach conforms to the 
emerging learn-confirm paradigm in the translation of molecular biomarkers, 
in which their integration into clinical practice requires validation in 
independent populations [109-116]. 
• The enhanced sensitivity of qRT-PCR [107], with its advantageous tissue 
volume sampling and ability to discriminate single cells, may identify occult 
tumor deposits in lymph nodes below the threshold of prognostic risk [2], 
limiting the specificity of molecular staging [45, 93].  This is reflected in the 
detection of occult metastases in 87% pN0 patients, most of whom will not 
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develop recurrent disease [2].  There is an emerging paradigm that goes 
beyond the categorical (yes/no) presence of tumor cells, to quantify 
metastatic tumor burden (how much) to more accurately stratify risk [93].  In 
that context, qRT-PCR provides a unique opportunity to quantify occult tumor 
burden across the regional lymph node network to establish prognostic risk in 
pN0 patients. 
• Beyond prognosis, there is an established relationship between nodal 
metastases and therapeutic benefit in colon cancer patients.  While stage III 
patients treated with adjuvant therapy exhibit better survival outcomes, there 
continues to be ambiguity about the application of adjuvant therapy to pN0 
patients [2, 3, 6, 9, 20, 22, 23].  Indeed, the heterogeneity of therapeutic 
benefit in pN0 patients may reflect a contribution of inaccurate staging [4, 5, 
21, 24, 43-45].  In our prospective trial [45], GUCY2C qRT-PCR identified a 
subset of pN0 patients whose clinical outcomes matched that of stage III 
patients, staged by established criteria.  Typically, those patients receive 
adjuvant therapy suggesting that if pN0 patients at similar risk could be 
identified, they too could benefit from adjuvant chemotherapy.  In the 
future, studies will define whether occult lymph node metastases detected 
by GUCY2C qRT-PCR is a predictive marker of chemotherapeutic benefit 
[93].  These studies will determine if, among patients with occult lymph node 
metastases, those who receive chemotherapy have better clinical outcomes 
than those who do not. 
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• Most [2, 3, 96-102] studies support the critical relationship between the 
number of lymph nodes collected at staging colectomy and prognostic risk, 
although the precise number required for optimum patient management is 
not yet defined [102].  In contrast, the emergence of limited access 
procedures like laparoscopy-assisted colectomy restricts the collection of 
lymph nodes for staging [105].  The development of molecular staging, 
providing a rich source of prognostic and predictive information, underscores 
the importance of defining the number of lymph nodes required to optimize 
these new analyses.  In turn, these molecular innovations in staging will inform 
the co-evolution of advancements in surgical management, driving the 
technical specifications of limited access surgery to optimize lymph node 
yields, producing the best surgical and staging solutions for patients. 
• Molecular staging offers a unique opportunity to prioritize emerging complex 
resource-intensive analyses of primary tumors to optimize cost-effective 
patient management [45].  In that context, analyses of primary tumors to 
define mutations, gene expression and epigenetic profiles, and proteomic 
signatures to stratify risk, predict responses to chemotherapy, and 
individualize targeted biological interventions, will best be applied to patients 
harboring occult nodal metastases, rather than to those free of disease [117-
121].  Thus, future studies will examine the utility of a sequential diagnostic 
algorithm, in which all pN0 patients first are staged using GUCY2C qRT-PCR, 
to determine if they have clinically significant nodal metastases, followed by 
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pharmacogenomic testing only of those patients at risk, to identify 
therapeutic interventions best matched to the biology of their tumors [46]. 
• Preliminary studies are compelling that molecular staging by comprehensive 
GUCY2C qRT-PCR lymph node analysis identifies pN0 patients at increased 
risk of developing recurrent disease.  However, qRT-PCR is an emerging 
molecular platform that has not yet found broad dissemination to primary 
and secondary medical centers, raising a question of the limitations to 
implementation of molecular staging as a clinical standard of practice.  In 
that context, molecular diagnostics is a burgeoning $14 billion dollar industry, 
growing at more than 10% each year [122, 123].  The number of esoteric 
molecular diagnostic tests approved by the FDA annually is increasing 
exponentially, from 72 in 2006 to 134 in 2009 [124].  Further, the number of 
laboratory-developed (“home brew”) molecular diagnostic tests exceeded 
1,400 in 2009 [125].  In that context, it is anticipated that, like the vast majority 
of these esoteric molecular diagnostic tests, which include qRT-PCR, staging 
by GUCY2C lymph node analysis will be broadly available to practitioners 
through central reference laboratories providing established expertise and 
validated analytic platforms that conform to prevailing regulatory and CMS 
reimbursement requirements. 
8.  Summary 
Traditional paradigms for staging patients with colorectal cancer incorporating 
standard histopathological assessment of regional lymph nodes underestimate 
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the extent of metastatic disease, reflected by 25-30% of pN0 patients 
developing recurrent disease [93].  Limitations of traditional staging paradigms, 
including volume of tissue assessed and analytic sensitivity, can be eliminated 
by employing disease-specific markers and a powerful molecular amplification 
technology such as qRT-PCR [45, 93].  GUCY2C identifies metastatic colorectal 
cancer cells in extra-intestinal tissues, and occult lymph node metastases 
detected by GUCY2C qRT-PCR is an independent prognostic indicator for risk of 
disease recurrence in pN0 colorectal cancer patients [45, 93]. 
 27 
Acknowledgements 
This work was supported by funding from the National Institutes of Health 
(CA75123, CA95026 to SAW and CA112147 to TH) and Targeted Diagnostic & 
Therapeutics, Inc. (to SAW). AM was enrolled in the NIH-supported institutional 
K30 Training Program In Human Investigation (K30 HL004522) and was supported 
by NIH institutional award T32 GM08562 for Postdoctoral Training in Clinical 
Pharmacology. SAW is the Samuel M.V. Hamilton Endowed Professor. 
Financial and Competing Interest Disclosure 
SAW is a paid consultant to Merck, and the Chair (uncompensated) of the 
Scientific Advisory Board of Targeted Diagnostics and Therapeutics, Inc., which 
provided research funding that, in part, supported this study and which has a 
license to commercialize inventions related to this work.  DSW is a shareholder in 
Targeted Diagnostics and Therapeutics, Inc.
 28 
References 
1. Jemal, A, R Siegel, E Ward, T Murray, J Xu, MJ Thun: Cancer statistics, 2007. 
CA Cancer J Clin 57, 43-66 (2007). 
2. Compton, CC, FL Greene: The staging of colorectal cancer: 2004 and 
beyond. CA Cancer J Clin 54, 295-308 (2004). 
3. Greene, FL: AJCC Cancer Staging Manual. 6th ed. 2002, New York: 
Springer. 
4. Iddings, D, A Ahmad, D Elashoff, A Bilchik: The prognostic effect of 
micrometastases in previously staged lymph node negative (N0) 
colorectal carcinoma: a meta-analysis. Ann Surg Oncol 13, 1386-92 (2006). 
5. Nicastri, DG, JT Doucette, TE Godfrey, SJ Hughes: Is occult lymph node 
disease in colorectal cancer patients clinically significant? A review of the 
relevant literature. J Mol Diagn 9, 563-71 (2007). 
6. Meyerhardt, JA, RJ Mayer: Systemic therapy for colorectal cancer. N Engl 
J Med 352, 476-87 (2005). 
7. Ries, LA, PA Wingo, DS Miller et al.: The annual report to the nation on the 
status of cancer, 1973-1997, with a special section on colorectal cancer. 
Cancer 88, 2398-424 (2000). 
8. Sobrero, A, D Kerr, B Glimelius et al.: New directions in the treatment of 
colorectal cancer: a look to the future. Eur J Cancer 36, 559-66 (2000). 
9. Wolpin, BM, JA Meyerhardt, HJ Mamon, RJ Mayer: Adjuvant treatment of 
colorectal cancer. CA Cancer J Clin 57, 168-85 (2007). 
 29 
10. Allee, PE, JE Tepper, LL Gunderson, JE Munzenrider: Postoperative 
radiation therapy for incompletely resected colorectal carcinoma. Int J 
Radiat Oncol Biol Phys 17, 1171-6 (1989). 
11. Dukes, CE, HJ Bussey: The spread of rectal cancer and its effect on 
prognosis. Br J Cancer 12, 309-20 (1958). 
12. Galandiuk, S, HS Wieand, CG Moertel et al.: Patterns of recurrence after 
curative resection of carcinoma of the colon and rectum. Surg Gynecol 
Obstet 174, 27-32 (1992). 
13. Minsky, BD, C Mies, TA Rich, A Recht, JT Chaffey: Potentially curative 
surgery of colon cancer: the influence of blood vessel invasion. J Clin 
Oncol 6, 119-27 (1988). 
14. Newland, RC, PH Chapuis, MT Pheils, JG MacPherson: The relationship of 
survival to staging and grading of colorectal carcinoma: a prospective 
study of 503 cases. Cancer 47, 1424-9 (1981). 
15. Olson, RM, NP Perencevich, AW Malcolm, JT Chaffey, RE Wilson: Patterns 
of recurrence following curative resection of adenocarcinoma of the 
colon and rectum. Cancer 45, 2969-74 (1980). 
16. Phillips, RK, R Hittinger, L Blesovsky, JS Fry, LP Fielding: Large bowel cancer: 
surgical pathology and its relationship to survival. Br J Surg 71, 604-10 
(1984). 
17. Rubio, CA, S Emas, G Nylander: A critical reappraisal of Dukes' 
classification. Surg Gynecol Obstet 145, 682-4 (1977). 
 30 
18. Sinicrope, FA, SM Sugarman: Role of adjuvant therapy in surgically 
resected colorectal carcinoma. Gastroenterology 109, 984-93 (1995). 
19. Willett, CG, JE Tepper, AM Cohen, E Orlow, CE Welch: Failure patterns 
following curative resection of colonic carcinoma. Ann Surg 200, 685-90 
(1984). 
20. Andre, T, C Boni, L Mounedji-Boudiaf et al.: Oxaliplatin, fluorouracil, and 
leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350, 
2343-51 (2004). 
21. Bilchik, AJ, DS Hoon, S Saha et al.: Prognostic impact of micrometastases 
in colon cancer: interim results of a prospective multicenter trial. Ann Surg 
246, 568-75; discussion 575-7 (2007). 
22. Mamounas, E, S Wieand, N Wolmark et al.: Comparative efficacy of 
adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon 
cancer: results from four National Surgical Adjuvant Breast and Bowel 
Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 17, 
1349-55 (1999). 
23. Quasar Collaborative, G, R Gray, J Barnwell et al.: Adjuvant 
chemotherapy versus observation in patients with colorectal cancer: a 
randomised study. Lancet 370, 2020-9 (2007). 
24. Iddings, D, A Bilchik: The biologic significance of micrometastatic disease 
and sentinel lymph node technology on colorectal cancer. J Surg Oncol 
96, 671-677 (2007). 
 31 
25. Jones, S, WD Chen, G Parmigiani et al.: Comparative lesion sequencing 
provides insights into tumor evolution. Proc Natl Acad Sci U S A 105, 4283-8 
(2008). 
26. Ratto, C, L Sofo, M Ippoliti et al.: Accurate lymph-node detection in 
colorectal specimens resected for cancer is of prognostic significance. Dis 
Colon Rectum 42, 143-54; discussion 154-8 (1999). 
27. Buie, WD, DA Rothernberger: Surveillance after curative resection o 
colorectal cancer: individualing follow-up. Gastrointestinal Endoscopy 
Clinics of North America 3, 691-713 (1993). 
28. Sloane, JP: Molecules and micrometastases. Lancet 345, 1255-6 (1995). 
29. Greenson, JK, CE Isenhart, R Rice, C Mojzisik, D Houchens, EW Martin, Jr.: 
Identification of occult micrometastases in pericolic lymph nodes of 
Duke's B colorectal cancer patients using monoclonal antibodies against 
cytokeratin and CC49. Correlation with long-term survival. Cancer 73, 563-
9 (1994). 
30. Liefers, GJ, AM Cleton-Jansen, CJ van de Velde et al.: Micrometastases 
and survival in stage II colorectal cancer. N Engl J Med 339, 223-8 (1998). 
31. Andre, T, D Sargent, J Tabernero et al.: Current issues in adjuvant 
treatment of stage II colon cancer. Ann Surg Oncol 13, 887-98 (2006). 
32. de Gramont, A, C Tournigand, T Andre, AK Larsen, C Louvet: Targeted 
agents for adjuvant therapy of colon cancer. Semin Oncol 33, S42-5 
(2006). 
 32 
33. de Gramont, A, C Tournigand, T Andre, AK Larsen, C Louvet: Adjuvant 
therapy for stage II and III colorectal cancer. Semin Oncol 34, S37-40 
(2007). 
34. Fuchs, CS, RJ Mayer: Adjuvant chemotherapy for colon and rectal 
cancer. Semin Oncol 22, 472-87 (1995). 
35. Krook, JE, CG Moertel, LL Gunderson et al.: Effective surgical adjuvant 
therapy for high-risk rectal carcinoma. N Engl J Med 324, 709-15 (1991). 
36. Moertel, CG, TR Fleming, JS Macdonald et al.: Levamisole and fluorouracil 
for adjuvant therapy of resected colon carcinoma. N Engl J Med 322, 352-
8 (1990). 
37. Wolmark, N, H Rockette, B Fisher et al.: The benefit of leucovorin-
modulated fluorouracil as postoperative adjuvant therapy for primary 
colon cancer: results from National Surgical Adjuvant Breast and Bowel 
Project protocol C-03. J Clin Oncol 11, 1879-87 (1993). 
38. Kopetz, S, GJ Chang, MJ Overman et al.: Improved survival in metastatic 
colorectal cancer is associated with adoption of hepatic resection and 
improved chemotherapy. J Clin Oncol (2009). 
39. Sargent, D, A Sobrero, A Grothey et al.: Evidence for cure by adjuvant 
therapy in colon cancer: observations based on individual patient data 
from 20,898 patients on 18 randomized trials. J Clin Oncol 27, 872-7 (2009). 
 33 
40. Benson, AB, 3rd, D Schrag, MR Somerfield et al.: American Society of 
Clinical Oncology recommendations on adjuvant chemotherapy for 
stage II colon cancer. J Clin Oncol 22, 3408-19 (2004). 
41. Figueredo, A, ML Charette, J Maroun, MC Brouwers, L Zuraw: Adjuvant 
therapy for stage II colon cancer: a systematic review from the Cancer 
Care Ontario Program in evidence-based care's gastrointestinal cancer 
disease site group. J Clin Oncol 22, 3395-407 (2004). 
42. Winn, R, J McClure: The NCCN clinical practice guidelines in oncology. J 
Natl Comprehensive Cancer Network 1,(2005). 
43. Frick, GS, GM Pitari, DS Weinberg, T Hyslop, S Schulz, SA Waldman: 
Guanylyl cyclase C: a molecular marker for staging and postoperative 
surveillance of patients with colorectal cancer. Expert Rev Mol Diagn 5, 
701-13 (2005). 
44. Gelmann, A, R Desnoyers, B Cagir, D Weinberg, BM Boman, SA Waldman: 
Colorectal cancer staging and adjuvant chemotherapy. Expert Opin 
Pharmacother 1, 737-55 (2000). 
45. Waldman, SA, T Hyslop, S Schulz et al.: Association of GUCY2C expression 
in lymph nodes with time to recurrence and disease-free survival in pN0 
colorectal cancer. JAMA 301, 745-52 (2009). 
46. Allegra, CJ, JM Jessup, MR Somerfield et al.: American Society of Clinical 
Oncology provisional clinical opinion: Testing for KRAS gene mutations in 
patients with metastatic colorectal carcinoma to predict response to anti-
 34 
epidermal growth factor receptor monoclonal antibody therapy. J Clin 
Oncol 27, 2091-2096 (2009). 
47. Cagir, B, A Gelmann, J Park et al.: Guanylyl cyclase C messenger RNA is a 
biomarker for recurrent stage II colorectal cancer. Ann Intern Med 131, 
805-12 (1999). 
48. Almenoff, JS, SI Williams, LA Scheving, AK Judd, GK Schoolnik: Ligand-
based histochemical localization and capture of cells expressing heat-
stable enterotoxin receptors. Mol Microbiol 8, 865-73 (1993). 
49. Carrithers, SL, MT Barber, S Biswas et al.: Guanylyl cyclase C is a selective 
marker for metastatic colorectal tumors in human extraintestinal tissues. 
Proc Natl Acad Sci U S A 93, 14827-32 (1996). 
50. Carrithers, SL, SJ Parkinson, S Goldstein, P Park, DC Robertson, SA 
Waldman: Escherichia coli heat-stable toxin receptors in human colonic 
tumors. Gastroenterology 107, 1653-61 (1994). 
51. Cohen, MB, A Guarino, R Shukla, RA Giannella: Age-related differences in 
receptors for Escherichia coli heat-stable enterotoxin in the small and 
large intestine of children. Gastroenterology 94, 367-73 (1988). 
52. Cohen, MB, MS Moyer, M Luttrell, RA Giannella: The immature rat small 
intestine exhibits an increased sensitivity and response to Escherichia coli 
heat-stable enterotoxin. Pediatr Res 20, 555-60 (1986). 
 35 
53. Guarino, A, M Cohen, M Thompson, K Dharmsathaphorn, R Giannella: T84 
cell receptor binding and guanyl cyclase activation by Escherichia coli 
heat-stable toxin. Am J Physiol 253, G775-80 (1987). 
54. Guarino, A, MB Cohen, RA Giannella: Small and large intestinal guanylate 
cyclase activity in children: effect of age and stimulation by Escherichia 
coli heat-stable enterotoxin. Pediatr Res 21, 551-5 (1987). 
55. Guarino, A, MB Cohen, G Overmann, MR Thompson, RA Giannella: 
Binding of E. coli heat-stable enterotoxin to rat intestinal brush borders and 
to basolateral membranes. Dig Dis Sci 32, 1017-26 (1987). 
56. Lucas, KA, GM Pitari, S Kazerounian et al.: Guanylyl cyclases and signaling 
by cyclic GMP. Pharmacol Rev 52, 375-414 (2000). 
57. Rao, MC, S Guandalini, PL Smith, M Field: Mode of action of heat-stable 
Escherichia coli enterotoxin. Tissue and subcellular specificities and role of 
cyclic GMP. Biochim Biophys Acta 632, 35-46 (1980). 
58. Carrithers, SL, CE Ott, MJ Hill et al.: Guanylin and uroguanylin induce 
natriuresis in mice lacking guanylyl cyclase-C receptor. Kidney Int 65, 40-
53 (2004). 
59. Field, M: Mechanisms of action of cholera and Escherichia coli 
enterotoxins. Am J Clin Nutr 32, 189-96 (1979). 
60. Field, M, LH Graf, Jr., WJ Laird, PL Smith: Heat-stable enterotoxin of 
Escherichia coli: in vitro effects on guanylate cyclase activity, cyclic GMP 
 36 
concentration, and ion transport in small intestine. Proc Natl Acad Sci U S 
A 75, 2800-4 (1978). 
61. Guerrant, RL, JM Hughes, B Chang, DC Robertson, F Murad: Activation of 
intestinal guanylate cyclase by heat-stable enterotoxin of Escherichia coli: 
studies of tissue specificity, potential receptors, and intermediates. J Infect 
Dis 142, 220-8 (1980). 
62. Hughes, JM, F Murad, B Chang, RL Guerrant: Role of cyclic GMP in the 
action of heat-stable enterotoxin of Escherichia coli. Nature 271, 755-6 
(1978). 
63. Kuno, T, Y Kamisaki, SA Waldman, J Gariepy, G Schoolnik, F Murad: 
Characterization of the receptor for heat-stable enterotoxin from 
Escherichia coli in rat intestine. J Biol Chem 261, 1470-6 (1986). 
64. Schulz, S, CK Green, PS Yuen, DL Garbers: Guanylyl cyclase is a heat-
stable enterotoxin receptor. Cell 63, 941-8 (1990). 
65. Li, P, JE Lin, I Chervoneva, S Schulz, SA Waldman, GM Pitari: Homeostatic 
control of the crypt-villus axis by the bacterial enterotoxin receptor 
guanylyl cyclase C restricts the proliferating compartment in intestine. Am 
J Pathol 171, 1847-1858 (2007). 
66. Li, P, JE Lin, AE Snook et al.: Colorectal cancer as a paracrine deficiency 
syndrome amenable to oral hormone replacement therapy. Clinical 
Translational Science 1, 163-167 (2008). 
 37 
67. Li, P, JE Lin, AE Snook, S Schulz, GM Pitari, SA Waldman: Can colorectal 
cancer be prevented or treated by oral hormone replacement therapy? . 
Current Molecular Pharmacology 2, 285-292 (2008). 
68. Li, P, S Schulz, A Bombonati et al.: Guanylyl cyclase C suppresses intestinal 
tumorigenesis by restricting proliferation and maintaining genomic 
integrity. Gastroenterology 133, 599-607 (2007). 
69. Lin, EJ, P Li, AE Snook, S Schulz, GM Pitari, SA Waldman: Guanylyl cyclase C 
in colorectal cancer: susceptibility gene and potential therapeutic target. 
Future Oncology 5, 509-522 (2009). 
70. Lin, JE, P Li, AE Snook et al.: GUCY2C establishes lineage dependence in 
intestinal tumorigenesis through AKT. Gastroenterology 138, 241-254 (2010). 
71. Pitari, GM, RI Baksh, DM Harris, P Li, S Kazerounian, SA Waldman: 
Interruption of homologous desensitization in cyclic guanosine 3',5'-
monophosphate signaling restores colon cancer cytostasis by bacterial 
enterotoxins. Cancer Res 65, 11129-35 (2005). 
72. Pitari, GM, MD Di Guglielmo, J Park, S Schulz, SA Waldman: Guanylyl 
cyclase C agonists regulate progression through the cell cycle of human 
colon carcinoma cells. Proc Natl Acad Sci U S A 98, 7846-51 (2001). 
73. Pitari, GM, P Li, JE Lin et al.: The paracrine hormone hypothesis of 
colorectal cancer. Clin Pharmacol Ther 82, 441-7 (2007). 
 38 
74. Pitari, GM, JE Lin, FJ Shah et al.: Enterotoxin preconditioning restores 
calcium-sensing receptor-mediated cytostasis in colon cancer cells. 
Carcinogenesis 29, 1601-1607 (2008). 
75. Pitari, GM, LV Zingman, DM Hodgson et al.: Bacterial enterotoxins are 
associated with resistance to colon cancer. Proc Natl Acad Sci U S A 100, 
2695-9 (2003). 
76. Shailubhai, K, HH Yu, K Karunanandaa et al.: Uroguanylin treatment 
suppresses polyp formation in the Apc(Min/+) mouse and induces 
apoptosis in human colon adenocarcinoma cells via cyclic GMP. Cancer 
Res 60, 5151-7 (2000). 
77. Steinbrecher, KA, SA Wowk, JA Rudolph, DP Witte, MB Cohen: Targeted 
inactivation of the mouse guanylin gene results in altered dynamics of 
colonic epithelial proliferation. Am J Pathol 161, 2169-78 (2002). 
78. Birkenkamp-Demtroder, K, L Lotte Christensen, S Harder Olesen et al.: 
Gene expression in colorectal cancer. Cancer Research 62, 4352-63 
(2002). 
79. Cohen, MB, JA Hawkins, DP Witte: Guanylin mRNA expression in human 
intestine and colorectal adenocarcinoma. Lab Invest 78, 101-8 (1998). 
80. Notterman, DA, U Alon, AJ Sierk, AJ Levine: Transcriptional gene expression 
profiles of colorectal adenoma, adenocarcinoma, and normal tissue 
examined by oligonucleotide arrays. Cancer Res 61, 3124-30 (2001). 
 39 
81. Steinbrecher, KA, TM Tuohy, K Heppner Goss et al.: Expression of guanylin is 
downregulated in mouse and human intestinal adenomas. Biochem 
Biophys Res Commun 273, 225-30 (2000). 
82. Wilson, C, S Schulz, Hyslop, SA Waldman, Silencing of guanylin and 
uroguanylin expression in colon cancer. 2009. p. Submitted. 
83. Lin, EJ, P Li, AE Snook, S Schulz, GM Pitari, SA Waldman: Guanylyl cyclase C 
in colorectal cancer: susceptibility gene and potential therapeutic target. 
Future Oncology  In press (2009). 
84. Birbe, R, JP Palazzo, R Walters, D Weinberg, S Schulz, SA Waldman: 
Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and 
adenocarcinoma of the gastrointestinal tract. Hum Pathol 36, 170-9 
(2005). 
85. Fava, TA, R Desnoyers, S Schulz et al.: Ectopic expression of guanylyl 
cyclase C in CD34+ progenitor cells in peripheral blood. J Clin Oncol 19, 
3951-9 (2001). 
86. Waldman, SA, M Barber, J Pearlman, J Park, R George, SJ Parkinson: 
Heterogeneity of guanylyl cyclase C expressed by human colorectal 
cancer cell lines in vitro. Cancer Epidemiol Biomarkers Prev 7, 505-14 
(1998). 
87. Waldman, SA, B Cagir, J Rakinic et al.: Use of guanylyl cyclase C for 
detecting micrometastases in lymph nodes of patients with colon cancer. 
Dis Colon Rectum 41, 310-5 (1998). 
 40 
88. Schulz, S, T Hyslop, J Haaf et al.: A validated quantitative assay to detect 
occult micrometastases by reverse transcriptase-polymerase chain 
reaction of guanylyl cyclase C in patients with colorectal cancer. Clin 
Cancer Res 12, 4545-52 (2006). 
89. Witek, ME, K Nielsen, R Walters et al.: The putative tumor suppressor Cdx2 is 
overexpressed by human colorectal adenocarcinomas. Clin Cancer Res 
11, 8549-56 (2005). 
90. Phillips, B, C Ball, D Sackett et al., Levels of Evidence 2009, Oxford Centre 
for Evidence-based Medicine  
91. Chervoneva, I, Y Li, B Iglewicz, S Waldman, T Hyslop: Relative 
quantification based on logistic models for individual polymerase chain 
reactions. Stat Med 26, 5596-611 (2007). 
92. Chervoneva, I, T Hyslop, B Iglewicz et al.: Statistical algorithm for assuring 
similar efficiency in standards and samples for absolute quantification by 
real-time reverse transcription polymerase chain reaction. Anal Biochem 
348, 198-208 (2006). 
93. Mejia, A, S Schulz, T Hyslop, DS Weinberg, SA Waldman: GUCY2C reverse 
transcriptase PCR to stage pN0 colorectal cancer patients. Expert Rev Mol 
Diagn 9, 777-85 (2009). 
94. Moertel, CG, JR O'Fallon, VL Go, MJ O'Connell, GS Thynne: The 
preoperative carcinoembryonic antigen test in the diagnosis, staging, and 
prognosis of colorectal cancer. Cancer 58, 603-10 (1986). 
 41 
95. Punt, CJ, M Buyse, CH Kohne et al.: Endpoints in adjuvant treatment trials: 
a systematic review of the literature in colon cancer and proposed 
definitions for future trials. J Natl Cancer Inst 99, 998-1003 (2007). 
96. Chang, GJ, MA Rodriguez-Bigas, JM Skibber, VA Moyer: Lymph node 
evaluation and survival after curative resection of colon cancer: 
systematic review. J Natl Cancer Inst 99, 433-41 (2007). 
97. Govindarajan, A, NN Baxter: Lymph node evaluation in early-stage colon 
cancer. Clin Colorectal Cancer 7, 240-6 (2008). 
98. Johnson, PM, GA Porter, R Ricciardi, NN Baxter: Increasing negative lymph 
node count is independently associated with improved long-term survival 
in stage IIIB and IIIC colon cancer. J Clin Oncol 24, 3570-5 (2006). 
99. Le Voyer, TE, ER Sigurdson, AL Hanlon et al.: Colon cancer survival is 
associated with increasing number of lymph nodes analyzed: a 
secondary survey of intergroup trial INT-0089. J Clin Oncol 21, 2912-9 
(2003). 
100. Swanson, RS, CC Compton, AK Stewart, KI Bland: The prognosis of T3N0 
colon cancer is dependent on the number of lymph nodes examined. 
Ann Surg Oncol 10, 65-71 (2003). 
101. Tsikitis, VL, DL Larson, BG Wolff et al.: Survival in stage III colon cancer is 
independent of the total number of lymph nodes retrieved. J Am Coll Surg 
208, 42-7 (2009). 
 42 
102. Vather, R, T Sammour, A Kahokehr, AB Connolly, AG Hill: Lymph node 
evaluation and long-term survival in Stage II and Stage III colon cancer: a 
national study. Ann Surg Oncol 16, 585-93 (2009). 
103. Brown, HG, TM Luckasevic, DS Medich, JP Celebrezze, SM Jones: Efficacy 
of manual dissection of lymph nodes in colon cancer resections. Mod 
Pathol 17, 402-6 (2004). 
104. Herrera-Ornelas, L, J Justiniano, N Castillo, NJ Petrelli, JP Stulc, A Mittelman: 
Metastases in small lymph nodes from colon cancer. Arch Surg 122, 1253-6 
(1987). 
105. Bilimoria, KY, DJ Bentrem, H Nelson et al.: Use and outcomes of 
laparoscopic-assisted colectomy for cancer in the United States. Arch 
Surg 143, 832-9; discussion 839-40 (2008). 
106. Hitchcock, CL, J Sampsel, DC Young, EW Martin, Jr., MW Arnold: 
Limitations with light microscopy in the detection of colorectal cancer 
cells. Dis Colon Rectum 42, 1046-52 (1999). 
107. Nolan, T, RE Hands, SA Bustin: Quantification of mRNA using real-time RT-
PCR. Nat Protoc 1, 1559-82 (2006). 
108. Abati, A, LA Liotta: Looking forward in diagnostic pathology: the 
molecular superhighway. Cancer 78, 1-3 (1996). 
109. Krishna, R, G Herman, JA Wagner: Accelerating drug development using 
biomarkers: a case study with sitagliptin, a novel DPP4 inhibitor for type 2 
diabetes. AAPS J 10, 401-9 (2008). 
 43 
110. Lee, JW, V Devanarayan, YC Barrett et al.: Fit-for-purpose method 
development and validation for successful biomarker measurement. 
Pharm Res 23, 312-28 (2006). 
111. Lee, JW, RS Weiner, JM Sailstad et al.: Method validation and 
measurement of biomarkers in nonclinical and clinical samples in drug 
development: a conference report. Pharm Res 22, 499-511 (2005). 
112. Wagner, JA: Overview of biomarkers and surrogate endpoints in drug 
development. Dis Markers 18, 41-6 (2002). 
113. Wagner, JA: Back to the future: driving innovation in drug development. 
Clin Pharmacol Ther 83, 199-202 (2008). 
114. Wagner, JA: Strategic approach to fit-for-purpose biomarkers in drug 
development. Annu Rev Pharmacol Toxicol 48, 631-51 (2008). 
115. Wagner, JA, SA Williams, CJ Webster: Biomarkers and surrogate end points 
for fit-for-purpose development and regulatory evaluation of new drugs. 
Clin Pharmacol Ther 81, 104-7 (2007). 
116. Williams, SA, DE Slavin, JA Wagner, CJ Webster: A cost-effectiveness 
approach to the qualification and acceptance of biomarkers. Nat Rev 
Drug Discov 5, 897-902 (2006). 
117. Croner, RS, A Peters, WM Brueckl et al.: Microarray versus conventional 
prediction of lymph node metastasis in colorectal carcinoma. Cancer 
104, 395-404 (2005). 
 44 
118. Frigola, J, J Song, C Stirzaker, RA Hinshelwood, MA Peinado, SJ Clark: 
Epigenetic remodeling in colorectal cancer results in coordinate gene 
suppression across an entire chromosome band. Nat Genet 38, 540-9 
(2006). 
119. Jen, J, H Kim, S Piantadosi et al.: Allelic loss of chromosome 18q and 
prognosis in colorectal cancer. N Engl J Med 331, 213-21 (1994). 
120. Paik, S, S Shak, G Tang et al.: A multigene assay to predict recurrence of 
tamoxifen-treated, node-negative breast cancer. N Engl J Med 351, 2817-
26 (2004). 
121. Wang, Y, T Jatkoe, Y Zhang et al.: Gene expression profiles and molecular 
markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol 22, 
1564-71 (2004). 
122. Wilson, C, S Schulz, S Waldman: Cancer biomarkers: Where medicine, 
business, and public policy intersect. Biotechnology Healthcare (2007). 
123. Wilson, C, S Schulz, SA Waldman: Biomarker development, 
commercialization, and regulation: individualization of medicine lost in 
translation. Clin Pharmacol Ther 81, 153-5 (2007). 
124. Holland, C, FDA-cleared/approved molecular diagnostic tests. 2006, 
Association for Molecular Pathology. 
125. Quality, regulation and clinical utility of laboratory-developed tests. 2010, 
Agency for Healthcare Research and Qulaity (AHRQ). 
 
 45 
 
